SPT-300

DRUG2 trials

Sponsors

Seaport Therapeutics

Conditions

Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress

Phase 2

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

RecruitingNCT07065240

Seaport TherapeuticsMajor Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

Start: 2025-06-19End: 2027-03-01Target: 360Updated: 2026-09-14

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Enrolling by invitationNCT07161700

Seaport TherapeuticsMajor Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

Start: 2025-09-02End: 2027-05-01Target: 360Updated: 2026-08-17